GC Cell Corp
KOSDAQ:144510
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
GC Cell Corp
Stock-Based Compensation
GC Cell Corp
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
GC Cell Corp
KOSDAQ:144510
|
Stock-Based Compensation
₩121.4m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Stock-Based Compensation
₩23B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
19%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Stock-Based Compensation
₩2.8B
|
CAGR 3-Years
25%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Stock-Based Compensation
₩1.2B
|
CAGR 3-Years
56%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Stock-Based Compensation
₩5.5B
|
CAGR 3-Years
25%
|
CAGR 5-Years
39%
|
CAGR 10-Years
24%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Stock-Based Compensation
₩5.4B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
GC Cell Corp
Glance View
GC Cell Corp. engages in the research and development of cell curing agents and in the transport and sale of consignment inspection samples. The company is headquartered in Yongin, Gyeonggi-Do. The company went IPO on 2016-06-23. The firm operates its business through four segments. The Specimen Testing Service segment provides sample testing services, clinical trial services, and veterinary testing services. The Cell Therapy segment is engaged in cell culture and technology transfer business. The Cord Blood Storage segment is engaged in the cord blood storage business. The Other Business segment is engaged in bio-logistics business and others.
See Also
What is GC Cell Corp's Stock-Based Compensation?
Stock-Based Compensation
121.4m
KRW
Based on the financial report for Dec 31, 2025, GC Cell Corp's Stock-Based Compensation amounts to 121.4m KRW.
What is GC Cell Corp's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 3Y
-5%
Over the last year, the Stock-Based Compensation growth was -17%. The average annual Stock-Based Compensation growth rates for GC Cell Corp have been -5% over the past three years .
